Coxsackievirus and adenovirus receptor expression in non-malignant lung tissues and clinical lung cancers
Adenoviral vector mediated gene delivery has been applied in clinical trials and mechanistic studies to explore new treatment approaches for lung cancers. The expression of coxsackievirus adenovirus receptor (CAR), the primary receptor for the most commonly used adenovirus serotype 5 (Ad5)-based vectors, predominantly determines the permissiveness of lung cancer cells. CAR expression is also suggested to modulate tumor cell proliferation capacity. Here, we studied CAR expression in archival lung cancer specimens by using well-characterized CAR 72 antibodies. High levels of CAR expression were observed in most of the 32 cases of squamous cell carcinoma lung cancers and in all the five cases of small cell lung cancers investigated. In contrast, high levels of CAR expression were detected only in 6 of 22 adenocarcinoma lung cancers. The relative levels of CAR expression did not correlate with the pathologic grade in lung cancers, and was thus inconsistent with a role of modulating cancer cell proliferation. Of note, CAR expression was not detected in non-malignant alveolar cells. Our data suggest a preferred utility of Ad5 vector mediated gene delivery to squamous cell carcinoma lung cancers, small cell lung cancers, but not to the majority of adenocarcinoma lung cancers.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2006 |
|---|---|
| Erschienen: |
2006 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Journal of molecular histology - 37(2006), 3-4 vom: 28. Mai, Seite 153-60 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Yong [VerfasserIn] |
|---|
| Themen: |
Antibodies |
|---|
| Anmerkungen: |
Date Completed 03.03.2008 Date Revised 13.11.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM165896272 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM165896272 | ||
| 003 | DE-627 | ||
| 005 | 20231223105652.0 | ||
| 007 | tu | ||
| 008 | 231223s2006 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0553.xml |
| 035 | |a (DE-627)NLM165896272 | ||
| 035 | |a (NLM)17031523 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Yong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Coxsackievirus and adenovirus receptor expression in non-malignant lung tissues and clinical lung cancers |
| 264 | 1 | |c 2006 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 03.03.2008 | ||
| 500 | |a Date Revised 13.11.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Adenoviral vector mediated gene delivery has been applied in clinical trials and mechanistic studies to explore new treatment approaches for lung cancers. The expression of coxsackievirus adenovirus receptor (CAR), the primary receptor for the most commonly used adenovirus serotype 5 (Ad5)-based vectors, predominantly determines the permissiveness of lung cancer cells. CAR expression is also suggested to modulate tumor cell proliferation capacity. Here, we studied CAR expression in archival lung cancer specimens by using well-characterized CAR 72 antibodies. High levels of CAR expression were observed in most of the 32 cases of squamous cell carcinoma lung cancers and in all the five cases of small cell lung cancers investigated. In contrast, high levels of CAR expression were detected only in 6 of 22 adenocarcinoma lung cancers. The relative levels of CAR expression did not correlate with the pathologic grade in lung cancers, and was thus inconsistent with a role of modulating cancer cell proliferation. Of note, CAR expression was not detected in non-malignant alveolar cells. Our data suggest a preferred utility of Ad5 vector mediated gene delivery to squamous cell carcinoma lung cancers, small cell lung cancers, but not to the majority of adenocarcinoma lung cancers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies |2 NLM | |
| 650 | 7 | |a CLMP protein, human |2 NLM | |
| 650 | 7 | |a Coxsackie and Adenovirus Receptor-Like Membrane Protein |2 NLM | |
| 650 | 7 | |a Receptors, Virus |2 NLM | |
| 700 | 1 | |a Wang, Shizhong |e verfasserin |4 aut | |
| 700 | 1 | |a Bao, Yongyi |e verfasserin |4 aut | |
| 700 | 1 | |a Ni, Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Guan, Naifu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Jianzhong |e verfasserin |4 aut | |
| 700 | 1 | |a Salford, Leif G |e verfasserin |4 aut | |
| 700 | 1 | |a Widegren, Bengt |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Xiaolong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of molecular histology |d 2004 |g 37(2006), 3-4 vom: 28. Mai, Seite 153-60 |w (DE-627)NLM150024185 |x 1567-2387 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2006 |g number:3-4 |g day:28 |g month:05 |g pages:153-60 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2006 |e 3-4 |b 28 |c 05 |h 153-60 | ||